ERBB2 and breast carcinoma: Their clinical impact, is most pronounced in hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which accounts for approximately 70% of all breast malignancies (Parikh et al., 2024; Jia et al., 2025).